Fluconazole

166 interactions 13 explained in plain English
Also sold as: Diflucan
Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Jul 4, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Dofetilide Glasdegib Bedaquiline Sertraline Buprenorphine Ketoconazole Topical
16 Contraindicated 128 Major 22 Moderate
All (166) Contraindicated (16) Major (128) Moderate (22)

Contraindicated

Fluconazole Sertraline Explained Increased CYP3A4 substrate exposure and an increased risk of QT interval prolongation Details Fluconazole Buprenorphine Belbuca Explained An increased risk of QT interval prolongation, increased buprenorphine exposure and an increased risk of buprenorphine-related adv... Details Fluconazole Aripiprazole Injection Abilify Increased ARIPiprazole or ARIPiprazole lauroxil (prodrug of ARIPiprazole) exposure and an increased risk of QT interval prolongati... Details Fluconazole Alfuzosin UroXatral Increased alfuzosin exposure and an increased risk of QT interval prolongation Details Fluconazole Bedaquiline Sirturo Increased CYP3A4 substrate exposure and an increased risk of QT interval prolongation Details Fluconazole Dasatinib Phyrago An increased risk of QT interval prolongation and increased dasatinib exposure Details Fluconazole Deuruxolitinib Increased deuruxolitinib exposure and an increased risk of deuruxolitinib-related adverse effects such as thrombosis Details Fluconazole Dofetilide Tikosyn Increased CYP3A4 substrate exposure and an increased risk of QT interval prolongation Details Fluconazole Encorafenib Braftovi Increased encorafenib exposure, an increased risk of encorafenib-related adverse events and an increased risk of QT interval prolo... Details Fluconazole Entrectinib Rozlytrek Increased CYP3A4 substrate exposure and an increased risk of QT interval prolongation Details Fluconazole Glasdegib Daurismo Increased CYP3A4 substrate exposure and an increased risk of QT interval prolongation Details Fluconazole Granisetron Transdermal Patch Sancuso Increased granisetron exposure and an increased risk of QT interval prolongation Details Fluconazole Granisetron Injection Granisol Increased granisetron exposure and an increased risk of QT interval prolongation Details Fluconazole Ivabradine Corlanor Increased CYP3A4 substrate exposure and an increased risk of QT interval prolongation Details Fluconazole Ketoconazole Topical Extina® Foam Increased CYP3A4 substrate exposure and an increased risk of QT interval prolongation Details Fluconazole Lefamulin Xenleta Increased CYP3A4 substrate exposure and an increased risk of QT interval prolongation Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.